Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery

This study was undertaken to investigate the growth rate and clinical outcome of patients with a small renal mass (SRM) after delayed surgery. We reviewed the clinical records of 34 patients with SRMs ≤ 4 cm at diagnosis, who underwent delayed surgical intervention during surveillance from January 2...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2013, Vol.5 (default), p.85-89
Main Authors: Sugimoto, Koichi, Shimizu, Nobutaka, Oki, Takashi, Nose, Kazuhiro, Nishioka, Tsukasa, Adomi, Shogo, Ohzeki, Takayuki, Esa, Atsunobu, Uemura, Hirotsugu
Format: Article
Language:English
Subjects:
Cancer
Carcinoma, Renal cell
Clinical outcomes
delayed intervention
Development and progression
Diagnosis
Growth rate
Kidney cancer
natural history
Neoplastic processes
NMR
Nuclear magnetic resonance
Oncology, Experimental
Original Research
renal cell carcinoma
small renal mass
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was undertaken to investigate the growth rate and clinical outcome of patients with a small renal mass (SRM) after delayed surgery. We reviewed the clinical records of 34 patients with SRMs ≤ 4 cm at diagnosis, who underwent delayed surgical intervention during surveillance from January 2000 to December 2011. Radiographic evaluations using computed tomography (CT) scan and magnetic resonance imaging (MRI) were performed at least every 6 months, and the tumor size was determined at least twice. The mean follow-up time was 26.6 ± 18.6 months and mean tumor doubling time was 23.4 ± 16.0 months. Histopathological analysis revealed that 32 of the 34 patients were malignant in pT1aN0M0. Only one patient showed tumor recurrence, who subsequently died due to tumor progression. The growth rate of the small renal mass was slow in the majority of our patients. Delayed intervention does not have a detrimental effect on cancer-specific outcomes.
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S44221